Oncology Research International Limited (ORIL, ACN: 067 964 621) is an Australian, public, unlisted company.
The Company’s registered office is in Perth, WA, and the scientific program is driven and managed from Adelaide, SA.
ORIL’s founder Dr Michael Wayte was diagnosed with bowel cancer in 1986. Following a demanding and restrictive vegetarian diet with specific plant-based therapies, he made a full recovery. As a result he founded ORIL with the objective of researching plant-based therapies for cancer.
ORIL utilizes an outsourcing approach to development, tailored to its specific needs at any stage of the R&D program. This is a cost-effective approach which maximises the use of existing internal skills and complements them by engaging external services on a fee for service basis as needed.
ORIL’s CEO oversees a network of outsourced organizations which includes medical research institutes, universities, hospitals and specialist contract research organizations. Where possible, and provided the organization has the expertise for the particular project, the R&D is conducted in Australia.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia